Smith & Nephew Q3 2025 Trading Report Released
Ticker: SNNUF · Form: 6-K · Filed: Nov 6, 2025 · CIK: 845982
| Field | Detail |
|---|---|
| Company | Smith & Nephew PLC (SNNUF) |
| Form Type | 6-K |
| Filed Date | Nov 6, 2025 |
| Risk Level | low |
| Pages | 13 |
| Reading Time | 16 min |
| Key Dollar Amounts | $1,501 million, $1,412 million, $15, $20 million, $750 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: trading-update, quarterly-report, medical-devices
TL;DR
Smith & Nephew dropped its Q3 2025 trading update today - check the numbers.
AI Summary
Smith & Nephew plc released its Third Quarter 2025 Trading Report on November 6, 2025. The report details the company's performance and trading updates for the period ending September 30, 2025. Specific financial figures and operational highlights are expected within the full report.
Why It Matters
This report provides investors with an update on Smith & Nephew's recent financial performance and operational progress, influencing investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine trading update and does not appear to contain significant new risks or material adverse events.
Key Players & Entities
- Smith & Nephew plc (company) — Registrant and subject of the report
- November 6, 2025 (date) — Date of the filing and press release
- Third Quarter 2025 (period) — Reporting period for the trading update
FAQ
What is the specific revenue reported for the third quarter of 2025?
The filing states it is a trading report for the third quarter of 2025, but specific revenue figures are not detailed in the provided text, requiring reference to the full press release.
What were the key growth drivers mentioned in the Q3 2025 trading report?
The filing indicates a press release titled 'Smith+Nephew Third Quarter 2025 Trading Report' is included as an exhibit, which would contain details on growth drivers.
Does the report mention any changes in guidance for the full fiscal year 2025?
The provided text does not explicitly state whether guidance was updated, but the full trading report would typically address this.
What is the company's primary business as indicated by its SIC code?
Smith & Nephew plc's Standard Industrial Classification (SIC) code is 3842, which corresponds to Orthopedic, Prosthetic & Surgical Appliances & Supplies.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on November 6, 2025.
Filing Stats: 3,900 words · 16 min read · ~13 pages · Grade level 9.8 · Accepted 2025-11-06 06:00:25
Key Financial Figures
- $1,501 million — 25. Q3 Highlights 1,2 Q3 revenue of $1,501 million (Q3 2024: $1,412 million), representing
- $1,412 million — Q3 revenue of $1,501 million (Q3 2024: $1,412 million), representing 5.0% underlying revenue
- $15 — look includes an expected net impact of $15 to $20 million from tariffs in 2025, ba
- $20 million — cludes an expected net impact of $15 to $20 million from tariffs in 2025, based on announce
- $750 million — ree cash flow guidance raised to around $750 million (previously more than $600 million), re
- $600 million — ound $750 million (previously more than $600 million), reflecting strong working capital dis
- $500 million — perational efficiency Share Buyback $500 million share buyback completed, reflecting str
- $750 m — flow, which we now expect to be around $750 million, a more than five-fold increase s
- $20 m — remains a net headwind of around $15 to $20 million, as previously stated, and will c
- $5.8 billion — ountries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent
Filing Documents
- snn-20251106x6k.htm (6-K) — 351KB
- 0001104659-25-107254.txt ( ) — 352KB
Press release entitled " Smith+Nephew Third Quarter 2025 Trading Report ", dated November 6, 2025
Item 1. Press release entitled " Smith+Nephew Third Quarter 2025 Trading Report ", dated November 6, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Smith & Nephew plc (Registrant) Date: November 6, 2025 By: /s/ Helen Barraclough Helen Barraclough Company Secretary Smith+Nephew Third Quarter 2025 Trading Report 6 November 2025 Smith+Nephew (LSE:SN, NYSE:SNN) trading update for the third quarter ended 27 September 2025. Q3 Highlights 1,2 Q3 revenue of $1,501 million (Q3 2024: $1,412 million), representing 5.0% underlying revenue growth. Reported growth was 6.3% including 130bps currency tailwind. There were the same number of trading days as the prior year Orthopaedics underlying revenue growth was 4.1% (reported growth 5.1%), with strong growth from US Hip Implants continuing to offset weaker US Knee Implants Sports Medicine & ENT underlying revenue growth was 5.1% (reported growth 6.4%), with strong growth outside of China and VBP headwinds starting to abate Advanced Wound Management underlying revenue growth was 6.0% (reported growth 7.8%), led by double-digit growth in Advanced Wound Bioactives Continued higher cadence of product launches to underpin further growth Full Year Outlook: Revenue and Profit Margin Unchanged; Free Cash Flow Guidance Raised 1,2 We continue to expect full-year underlying revenue growth to be around 5.0% (reported growth around 5.7 % ), and trading profit margin to expand to between 19.0% and 20.0% o Outlook includes an expected net impact of $15 to $20 million from tariffs in 2025, based on announced measures, and mitigations, as previously stated Free cash flow guidance raised to around $750 million (previously more than $600 million), reflecting strong working capital discipline and operational efficiency Share Buyback $500 million share buyback completed, reflecting strong cash generation and balance sheet Capital Markets Days Capital Markets D
Forward-looking Statements
Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate chan